Patents by Inventor Alberto Cerri
Alberto Cerri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11730746Abstract: Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C1-C4) linear or branched alkyl or guanidine or guanidino (C1-C4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C?C; the thick line represents a bond in the ? configuration; the wavy line represents a bond both in the ? and ? configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.Type: GrantFiled: July 17, 2019Date of Patent: August 22, 2023Assignee: CVie Therapeutics LimitedInventors: Alberto Cerri, Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi, Antonio Zaza, Marcella Rocchetti, Carlotta Ronchi, Shih-Che Hsu
-
Publication number: 20230009312Abstract: Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the disclosed compounds are derivatives of androstane having the formula (I). Also disclosed herein are pharmaceutical compositions comprising one or more of the compounds of formula (I) for use for the treatment of heart failure.Type: ApplicationFiled: October 8, 2020Publication date: January 12, 2023Applicant: Windtree Therapeutics, Inc.Inventors: Alberto CERRI, Patrizia FERRARI, Mara FERRANDI, Paolo BARASSI, Giusseppe BIANCHI, Shih-Che HSU, Francesco PERI, Antonio ZAZA, Marcella ROCCHETTI, Andrea LURAGHI, Eleonora TORRE, Carlotta RONCHI
-
Publication number: 20210283147Abstract: Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C1-C4) linear or branched alkyl or guanidine or guanidino (C1-C4) linear or branched alkyl; with the proviso that the heterocycle ring is not furyl; n is 0 or 1; R is H or OH; the dotted line represents an optional double bond C?C; the thick line represents a bond in the ? configuration; the wavy line represents a bond both in the ? and ? configuration; their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors. The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.Type: ApplicationFiled: July 17, 2019Publication date: September 16, 2021Applicant: CVie Therapeutics LimitedInventors: Alberto CERRI, Giuseppe BIANCHI, Patrizia FERRARI, Mara FERRANDI, Paolo BARASSI, Antonio ZAZA, Marcella ROCCHETTI, Carlotta RONCHI, Shih-Che HSU
-
Patent number: 9127037Abstract: New crystalline forms of 17?-(3-Furyl)-5-?androstane-3?,14?,17?-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described.Type: GrantFiled: November 23, 2006Date of Patent: September 8, 2015Assignee: ROSTAQUO S.P.A.Inventors: Alberto Cerri, Silvia Armaroli, Marco Torri
-
Patent number: 8822692Abstract: The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients.Type: GrantFiled: July 26, 2013Date of Patent: September 2, 2014Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.Inventors: Alberto Cerri, Mauro Gobbini, Marco Torri, Patrizia Ferrari, Mara Ferrandi, Giuseppe Bianchi
-
Patent number: 8664210Abstract: New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.Type: GrantFiled: September 18, 2008Date of Patent: March 4, 2014Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Giuseppe Bianchi, Giorgio Fedrizzi, Patrizia Ferrari, Mauro Gobbini, Marco Torri, Giuseppe Marazzi, Walter Cabri
-
Patent number: 8609644Abstract: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.Type: GrantFiled: April 11, 2007Date of Patent: December 17, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Marco Torri, Silvia Armaroli, Leonardo Banfi, Giuseppe Bianchi, Giulio Carzana, Patrizia Ferrari, Rosamaria Michaeletti, Simona Sputore, Maria Pia Zappavigna
-
Publication number: 20130310423Abstract: The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients.Type: ApplicationFiled: July 26, 2013Publication date: November 21, 2013Applicant: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Mauro Gobbini, Marco Torri, Patrizia Ferrari, Mara Ferrandi, Giuseppe Bianchi
-
Patent number: 8536160Abstract: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.Type: GrantFiled: April 11, 2007Date of Patent: September 17, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Giorgio Fedrizzi, Alessandra Benicchio, Giuseppe Bianchi, Patrizia Ferrari, Mauro Gobbini, Rosamaria Micheletti, Marco Pozzi, Piero Enrico Scotti
-
Patent number: 8022203Abstract: New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.Type: GrantFiled: May 31, 2007Date of Patent: September 20, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Barbara Moro, Maco Torri, Giulio Carzana, Giuseppe Bianchi, Mara Ferrandi, Patrizia Ferrari, Maria Pia Zappavigna, Leonardo Banfi, Giuseppe Giacalone
-
Publication number: 20110053902Abstract: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.Type: ApplicationFiled: April 11, 2007Publication date: March 3, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Alberto Cerri, Marco Torri, Silvia Armaroli, Leonardo Banfi, Giuseppe Bianchi, Giulio Carzana, Patrizia Ferrari, Rosamaria Michaeletti, Simona Sputore, Maria Pia Zappavigna
-
Publication number: 20100324003Abstract: New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.Type: ApplicationFiled: September 18, 2008Publication date: December 23, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Alberto Cerri, Giuseppe Bianchi, Giorgio Fedrizzi, Patrizia Ferrari, Mauro Gobbini, Giuseppe Marazzi, Marco Torri, Walter Cabri
-
Publication number: 20090275542Abstract: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.Type: ApplicationFiled: April 11, 2007Publication date: November 5, 2009Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.Inventors: Alberto Cerri, Giorgio Fedrizzi, Alessandra Benicchio, Giuseppe Bianchi, Patrizia Ferrari, Mauro Gobbini, Rosamaria Micheletti, Marco Pozzi, Piero Enrico Scotti
-
Publication number: 20090209506Abstract: New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.Type: ApplicationFiled: May 31, 2007Publication date: August 20, 2009Inventors: Alberto Cerri, Barbara Moro, Maco Torri, Giulio Carzana, Giuseppe Bianchi, Mara Ferrandi, Patrizia Ferrari, Maria Pia Zappavigna, Leonardo Banfi, Giuseppe Giacalone
-
Publication number: 20080300228Abstract: New crystalline forms of 17?-(3-Furyl)-5-?androstane-3?,14?,17?-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described.Type: ApplicationFiled: November 23, 2006Publication date: December 4, 2008Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Alberto Cerri, Silvia Armaroli, Marco Torri
-
Patent number: 7247747Abstract: An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formu (I): where X1 and X2, which may be the same or different, are hydroxy, C1-C4 alkoxy, phenoxy, halogen, or X1 and X2, when taken together are an oxygen atom and the resulting compound is a derivative of succinic anhydride; Y is halogen, a mesyloxy or a tosyloxy group, and subsequent treatment with water, then with a base and then with trimethylamine.Type: GrantFiled: July 7, 2005Date of Patent: July 24, 2007Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Piero Melloni, Alberto Cerri, Marco Santagostino
-
Patent number: 6984739Abstract: An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formula (I): where X1 and X2, which may be the same or different, are hydroxy, C1–C4 alkoxy, phenoxy, halogen, or X1 and X2, when taken together are an oxygen atom and the resulting compound is a derivative of succinic anhydride; Y is halogen, a mesyloxy or a tosyloxy group, and subsequent treatment with water, then with a base and then with trimethylamine.Type: GrantFiled: November 20, 2003Date of Patent: January 10, 2006Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Piero Melloni, Alberto Cerri, Marco Santagostino
-
Publication number: 20050245762Abstract: An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formula (I): where X1 and X2, which may be the same or different, are hydroxy, C1-C4 alkoxy, phenoxy, halogen, or X1 and X2, when taken together are an oxygen atom and the resulting compound is a derivative of succinic anhydride; Y is halogen, a mesyloxy or a tosyloxy group, and subsequent treatment with water, then with a base and then with trimethylamine.Type: ApplicationFiled: July 7, 2005Publication date: November 3, 2005Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Piero Melloni, Alberto Cerri, Marco Santagostino
-
Publication number: 20040102645Abstract: An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formula (I): 1Type: ApplicationFiled: November 20, 2003Publication date: May 27, 2004Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Piero Melloni, Alberto Cerri, Marco Santagostino
-
Patent number: 6677476Abstract: An inner salt of L-carnitine is prepared by reduction, with a suitable reducing agent, of a compound of formula (I): where X1 and X2, which may be the same or different, are hydroxy, C1-C4 alkoxy, phenoxy, halogen, or X1 and X2, when taken together are an oxygen atom and the resulting compound is a derivative of succinic anhydride; Y is halogen, the mesyloxy or the tosyloxy group: and subsequent treatment with water, then with a base and then with trimethylamine.Type: GrantFiled: November 6, 2001Date of Patent: January 13, 2004Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Piero Melloni, Alberto Cerri, Marco Santagostino